vimarsana.com

Latest Breaking News On - Nasdaq casi - Page 2 : vimarsana.com

CASI Pharmaceuticals (NASDAQ:CASI) Receives New Coverage from Analysts at StockNews com

StockNews.com assumed coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note published on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright raised their target price on CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a report […]

CASI Pharmaceuticals (NASDAQ:CASI) Now Covered by Analysts at StockNews com

StockNews.com initiated coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright raised their target price on CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy rating in a research […]

CASI Pharmaceuticals (NASDAQ:CASI) Share Price Passes Above Two Hundred Day Moving Average of $3 93

CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $3.93 and traded as high as $5.50. CASI Pharmaceuticals shares last traded at $5.42, with a volume of 23,090 shares trading hands. Analyst Upgrades and Downgrades Several […]

CASI Pharmaceuticals (NASDAQ:CASI) Earns Hold Rating from Analysts at StockNews com

StockNews.com started coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report report published on Monday morning. The firm issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright raised their price target on CASI Pharmaceuticals from $10.00 to $12.00 and gave the stock a buy rating in a […]

CASI Pharmaceuticals (NASDAQ:CASI) Coverage Initiated at StockNews com

StockNews.com began coverage on shares of CASI Pharmaceuticals (NASDAQ:CASI – Free Report) in a research report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock. Separately, HC Wainwright boosted their target price on CASI Pharmaceuticals from $10.00 to $12.00 and gave the company a buy rating in a research […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.